Financial Performance - Citius Oncology reported a net loss of $7.7 million, or ($0.11) per share, for Q2 2025, compared to a net loss of $4.8 million, or ($0.07) per share, for Q2 2024[9]. - Stock-based compensation expense for Q2 2025 was $2.1 million, slightly up from $2.0 million in Q2 2024[8]. Expenses - Research and Development (R&D) expenses increased to $3.1 million for Q2 2025, up from $1.3 million in Q2 2024, primarily due to costs associated with drug substance batch expenses[6]. - General and Administrative (G&A) expenses rose to $2.2 million for Q2 2025, compared to $1.4 million in Q2 2024, driven by pre-commercial and commercial launch activities for LYMPHIR[7]. Cash and Liabilities - As of March 31, 2025, Citius Oncology had $112 in cash and cash equivalents and will need to secure additional capital to support operations beyond May 2025[5]. - The total current liabilities increased to $49.7 million as of March 31, 2025, from $32.7 million as of September 30, 2024[14]. - Citius Oncology's total assets were reported at $91.4 million as of March 31, 2025, compared to $84.4 million as of September 30, 2024[14]. Strategic Focus - The company is focused on the U.S. launch of LYMPHIR, which has an estimated initial market exceeding $400 million[10]. - Citius Oncology is actively pursuing discussions with potential commercial and strategic partners to enhance financial flexibility and support the launch of LYMPHIR[3]. - The company retained Jefferies LLC as an exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value[4].
TenX Keane Acquisition(TENK) - 2025 Q1 - Quarterly Results